• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results.

作者信息

Kampf D, Kahl A, Passlick J, Pustelnik A, Eckardt K U, Ehmer B, Jacobs C, Baumelou A, Grabensee B, Gahl G M

机构信息

Nephrologische Abteilung, Universitätsklinik Rudolf Virchow/Charlottenburg, Berlin.

出版信息

Contrib Nephrol. 1989;76:106-10; discussion 110-1. doi: 10.1159/000417886.

DOI:10.1159/000417886
PMID:2582776
Abstract
摘要

相似文献

1
Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results.重组人促红细胞生成素静脉、皮下和腹腔注射后的单剂量动力学。初步结果。
Contrib Nephrol. 1989;76:106-10; discussion 110-1. doi: 10.1159/000417886.
2
Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment.持续性非卧床腹膜透析（CAPD）患者静脉内、腹腔内及皮下注射重组促红细胞生成素的药代动力学。治疗依据。
Contrib Nephrol. 1989;76:112-20; discussion 120-1. doi: 10.1159/000417887.
3
Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lancet. 1989 Feb 25;1(8635):425-7. doi: 10.1016/s0140-6736(89)90014-7.
4
Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.
Pediatr Nephrol. 1993 Feb;7(1):61-4. doi: 10.1007/BF00861571.
5
Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.一项随机等效性研究，评估接受皮下注射人促红细胞生成素的血液透析患者直接转换为静脉注射阿法达贝泊汀的可能性。
Ann Pharmacother. 2009 Feb;43(2):228-34. doi: 10.1345/aph.1K664. Epub 2009 Jan 6.
6
Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.重组人促红细胞生成素在透析患者单次及多次皮下给药后的药代动力学
Nephron. 1992;61(4):393-8. doi: 10.1159/000186955.
7
Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).重组人促红细胞生成素（r-HuEPO）的临床药理学
Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):9S-14S.
8
Increased erythropoietin-alpha dose when switching from subcutaneous to intravenous administration: effect of serum albumin.
Clin Nephrol. 2008 May;69(5):347-53. doi: 10.5414/cnp69347.
9
Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析患者腹腔内、静脉内及皮下注射重组人促红细胞生成素的药代动力学
Am J Kidney Dis. 1993 Jun;21(6):635-42. doi: 10.1016/s0272-6386(12)80037-0.
10
[The pharmacokinetics of recombinant human erythropoietin].[重组人促红细胞生成素的药代动力学]
Ter Arkh. 1994;66(8):60-2.

引用本文的文献

1
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.促红细胞生成素刺激剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x.
2
Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.促红细胞生成素的药代动力学/药效学分析表明，治疗新生儿贫血时需要更高剂量。
Pediatr Int. 2009 Feb;51(1):25-32. doi: 10.1111/j.1442-200X.2008.02648.x.
3
The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.
皮下注射给予绵羊后，α- 达比加群酯主要通过淋巴管吸收。
Pharm Res. 2006 Sep;23(9):2060-6. doi: 10.1007/s11095-006-9064-8. Epub 2006 Aug 9.
4
Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.两种重组促红细胞生成素制剂在接受血液透析的终末期肾病贫血患者中的比较：一项平行、随机、双盲研究。
BMC Nephrol. 2005 May 23;6:5. doi: 10.1186/1471-2369-6-5.
5
Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.
Int Urol Nephrol. 1998;30(1):91-7. doi: 10.1007/BF02550285.
6
Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析期间的临床药代动力学
Clin Pharmacokinet. 1996 Oct;31(4):293-308. doi: 10.2165/00003088-199631040-00005.
7
Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.皮下注射后促红细胞生成素在血液透析患者中的药代动力学：长期治疗的影响。
Pharm World Sci. 1993 Dec 17;15(6):252-6. doi: 10.1007/BF01871126.
8
The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.重组人促红细胞生成素在不同部位皮下注射后的药代动力学。
Eur J Clin Pharmacol. 1994;46(4):333-7. doi: 10.1007/BF00194401.
9
Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).促红细胞生成素（重组人促红细胞生成素）的临床药代动力学
Clin Pharmacokinet. 1991 Feb;20(2):99-113. doi: 10.2165/00003088-199120020-00002.
10
The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.重组人促红细胞生成素在血液透析患者中的药代动力学和药效学
Br J Clin Pharmacol. 1992 Dec;34(6):499-508.